An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine
- 25 November 2005
- journal article
- Published by Wiley in European Journal of Neuroscience
- Vol. 22 (11) , 2775-2782
- https://doi.org/10.1111/j.1460-9568.2005.04470.x
Abstract
Fractalkine is a chemokine that is tethered to the extracellular surface of neurons. Fractalkine can be released, forming a diffusible signal. Spinal fractalkine (CX3CL1) is expressed by sensory afferents and intrinsic neurons, whereas its receptor (CX3CR1) is predominantly expressed by microglia. Pain enhancement occurs in response both to intrathecally administered fractalkine and to spinal fractalkine endogenously released by peripheral neuropathy. The present experiments examine whether fractalkine-induced pain enhancement is altered by a microglial inhibitor (minocycline) and/or by antagonists/inhibitors of three putative glial products implicated in pain enhancement: interleukin-1 (IL1), interleukin-6 (IL6) and nitric oxide (NO). In addition, it extends a prior study that demonstrated that intrathecal fractalkine-induced mechanical allodynia is blocked by a neutralizing antibody to the rat fractalkine receptor, CX3CR1. Here, intrathecal anti-CX3CR1 also blocked fractalkine-induced thermal hyperalgesia. Furthermore, blockade of microglial activation with minocycline prevented both fractalkine-induced mechanical allodynia (von Frey test) and thermal hyperalgesia (Hargreaves test). Microglial activation appears to lead to the release of IL1, given that pretreatment with IL1 receptor antagonist blocked both fractalkine-induced mechanical allodynia and thermal hyperalgesia. IL1 is not the only proinflammatory cytokine implicated, as a neutralizing antibody to rat IL6 also blocked fractalkine-induced pain facilitation. Lastly, NO appears to be importantly involved, as l-NAME, a broad-spectrum NO synthase inhibitor, also blocked fractalkine-induced effects. Taken together, these data support that neuronally released fractalkine enhances pain via activation of spinal cord glia. Thus, fractalkine may be a neuron-to-glia signal triggering pain facilitation.Keywords
This publication has 41 references indexed in Scilit:
- Immune and glial cell factors as pain mediators and modulatorsExperimental Neurology, 2005
- GLIA: A novel drug discovery target for clinical painNature Reviews Drug Discovery, 2003
- Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain11Published on the World Wide Web on 28 August 2000.Brain Research, 2000
- Fractalkine — a strange attractor in the chemokine landscapeImmunology Today, 1997
- Microglia: a sensor for pathological events in the CNSTrends in Neurosciences, 1996
- Preincubation with Substance P Induces Substance P-Stimulated Phosphatidylinositol Turnover in Cultured Cerebellar AstrocytesJournal of Neurochemistry, 1992
- Substance P‐Induced Release of Prostaglandins from Astrocytes: Regional Specialisation and Correlation with Phosphoinositol MetabolismJournal of Neurochemistry, 1991
- Activation of substance P receptors leads to membrane potential responses in cultured astrocytesGlia, 1989
- A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesiaPAIN®, 1988
- Efficient estimation of sensory thresholdsBehavior Research Methods, Instruments & Computers, 1986